DOI: 10.36347/sjams.2023.v11i07.013

Pages: 1278-1283

Chronic inflammatory bowel disease (IBD) is often accompanied by intestinal and systemic symptoms that are bothersome and impair the quality of life of patients and their families. The main objective of this study is to evaluate the quality of life of IBD patients followed in the hepato-gastroenterology department of the TANGER-TETOUAN-ALHOCEIMA university hospital. Materials and methods: This is a descriptive cross-sectional study, carried out in the hepato-gastroenterology department of the TANGER-TETOUAN-ALHOCEIMA university hospital, which included all patients with IBD confirmed on endoscopic and histological criteria, and who presented for consultation during the period from March 2022 to December 2022. Patients with psychiatric disorders were excluded from the study. Quality of life was assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ). The version used in our study has been translated into Moroccan dialectal Arabic and is currently being validated. Statistical and graphical analyses were performed using IBM SPSS Statistics 19 for Windows. Results: Our study included 100 patients with IBD. Crohn's disease was present in 62% of cases (n=62), and UC in 38% of cases (n=32). In our study, 24 patients (24%) were in remission at the time of data collection. The mean IBDQ-M score was 149.75, with extremes ranging from 66 to 217. Men had a higher mean score than women (155 versus 143; p=0.12). Patients aged over 50 had a lower score on average than patients aged under 50 (137 versus 150; p=0.3). CD patients had a better score than UC patients (152 versus 143; p=0.2). Patients in remission had a calculated sub-domain score of 61 versus 47 in relapsing patients, 28 versus 20 in the general symptoms sub-domain, 69 versus 50 for emotional functioning and 31 versus 25 for social functioning (p<0.001). Conclusion: Our study confirmed the impact of disease activity on HRQoL in IBD patients, irrespective of disease type.